BidaskClub lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a research note released on Thursday, March 15th.
Several other research analysts also recently weighed in on the stock. HC Wainwright set a $37.00 price target on shares of Audentes Therapeutics and gave the stock a buy rating in a research report on Friday, March 9th. Cowen reiterated a buy rating on shares of Audentes Therapeutics in a research report on Friday, March 9th. Zacks Investment Research upgraded shares of Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 price target on the stock in a research report on Thursday, March 8th. William Blair reiterated a buy rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. Finally, ValuEngine downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Audentes Therapeutics currently has an average rating of Buy and an average target price of $35.56.
Audentes Therapeutics stock traded down $0.83 during midday trading on Thursday, reaching $28.11. 139,113 shares of the company traded hands, compared to its average volume of 355,474. The company has a market cap of $1,061.35, a price-to-earnings ratio of -8.27 and a beta of 1.39. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.09. equities research analysts predict that Audentes Therapeutics will post -3.43 earnings per share for the current fiscal year.
In related news, major shareholder Orbimed Advisors Llc sold 421,638 shares of the firm’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.17, for a total transaction of $14,829,008.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Louis G. Lange sold 48,000 shares of the firm’s stock in a transaction on Monday, March 26th. The shares were sold at an average price of $28.89, for a total transaction of $1,386,720.00. Following the transaction, the director now directly owns 414,231 shares of the company’s stock, valued at $11,967,133.59. The disclosure for this sale can be found here. Insiders have sold 1,138,107 shares of company stock valued at $39,502,022 over the last ninety days. 47.30% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of BOLD. Vanguard Group Inc. grew its stake in shares of Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after buying an additional 383,837 shares in the last quarter. Farallon Capital Management LLC purchased a new position in shares of Audentes Therapeutics in the 4th quarter worth $9,989,000. Citadel Advisors LLC grew its stake in shares of Audentes Therapeutics by 206.2% in the 4th quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock worth $10,612,000 after buying an additional 228,667 shares in the last quarter. Artal Group S.A. purchased a new position in shares of Audentes Therapeutics in the 3rd quarter worth $5,602,000. Finally, BlackRock Inc. grew its stake in shares of Audentes Therapeutics by 13.2% in the 4th quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock worth $42,452,000 after buying an additional 158,576 shares in the last quarter. 66.96% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/audentes-therapeutics-bold-downgraded-by-bidaskclub-to-buy.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.